Company Filing History:
Years Active: 2000-2009
Title: The Innovations of Eugene Metchetner
Introduction
Eugene Metchetner is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, his work has had a profound impact on the understanding and treatment of multidrug resistance in cancer.
Latest Patents
Metchetner's latest patents include a monoclonal antibody targeting a human MDR1 multidrug resistance gene product. This innovation involves a hybridoma, known as 'UIC2 hybridoma' (ATCC Accession No. HB11027), which produces monoclonal antibodies (referred to as 'UIC2 mAb'). These antibodies are directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells. The UIC2 mAb can be utilized to detect and isolate multidrug-resistant primate cells and human mdr1 gene products. Furthermore, it has the potential to reverse multidrug resistance in primate cells, including those found in multidrug-resistant human tumors.
Career Highlights
Eugene Metchetner has established a successful career in the field of biotechnology. He is affiliated with the University of Illinois, where he continues to advance research in monoclonal antibodies and their applications in combating drug resistance.
Collaborations
Metchetner has collaborated with Igor B Roninson, a fellow researcher in the field. Their joint efforts have contributed to the development of innovative solutions for addressing multidrug resistance in cancer treatment.
Conclusion
Eugene Metchetner's work exemplifies the importance of innovation in biotechnology. His contributions to the development of monoclonal antibodies have the potential to significantly impact cancer treatment and improve patient outcomes.